Direct renin inhibitor aliskiren flops as add-on therapy in systolic HF: ASTRONAUT

Signals of biomarker improvement and a differential clinical effect by diabetes status are highlights of the trial, but not efficacy for the primary end point: six-month CV death or heart-failure rehospitalization.
Source: theHeart.org - Category: Cardiology Source Type: news